GSK Hopes RECORD Sets Avandia Straight; Firm’s Diabetes Pipeline Bleak
Executive Summary
If GlaxoSmithKline's Avandia is brought down by a potential cardiovascular safety signal, the firm will not have diabetes products graduating from its pipeline in the near term to fill the void
You may also be interested in...
Merck, Wyeth Weather Stormy Q2 Despite Setbacks; Not All Fare So Well
Pharmaceutical companies had a relatively stable second quarter, despite several high-profile regulatory setbacks and failures during the period
Merck, Wyeth Weather Stormy Q2 Despite Setbacks; Not All Fare So Well
Pharmaceutical companies had a relatively stable second quarter, despite several high-profile regulatory setbacks and failures during the period
FDA Is Waiting On Internal Analysis Of Avandia Cardiovascular Safety Signal
FDA is not taking immediate regulatory action on an observed cardiovascular signal for GlaxoSmithKline's Avandia, as the agency feels the current labeling is sufficient until its own analysis of emerging safety data for the type 2 diabetes therapy is completed